Gilead avoided nearly $10 billion in taxes last year thanks to tax dodges
(By Ed Silverman for ST A T) Thanks to a pair of pricey hepatitis C treatments, Gilead Sciences has become
Read More
Part D/Prescription Drugs
Pfizer wins big in opioid deal with Chicago. But what does the city get?
(By Ed Silverman for ST A T) A t a meeting held last week to review the opioid epidemic, FDA
Read MoreFDA lets cancer trial resume after three patient deaths
(By Damian Garde for ST A T) F ederal regulators on Tuesday gave Juno Therapeutics the all-clear to resume testing
Read MoreExperimental drug shows promise for quick treatment of postpartum depression
(By Meghana Keshavan for ST A T) A n experimental drug touted as a breakthrough for treating severe postpartum depression
Read MoreDrug industry and Obamacare
The one key player in health care that escaped upheaval of Obamacare was the drug industry. With prescription drugs being
Read MoreRepublicans embrace the ‘Right to Try’ to get experimental medicines
(By Ed Silverman for ST A T) T he “Right to Try” movement may be embedded in the Republican Party
Read MoreFDA narrowly defines the ability of compounders to make approved medicines
(By Ed Silverman for ST A T) I n its latest to bid to set parameters around compounding, the US
Read MoreA Fair Plan For Fairer Drug Prices
(By Scott Gottlieb and Kavita Patel for Health Affairs Blog posted July 11, 2016) As the biological basis of more
Read MoreSounds Like A Good Idea? Regulating Drug Prices
(By Julie Rovner and Francis Ying for Kaiser Health News) This is the second in a series of videos about
Read More10 Essential Facts About Medicare and Prescription Drug Spending
(The Henry J. Kaiser Family Foundation, July 7, 2016) Prescription drugs play an important role in medical care for 57
Read More